Neovasc Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Neovasc stock.
View analyst ratings for Neovasc or view top-rated stocks.

Wall Street analysts have given Neovasc a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Neovasc wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Neovasc saw a decrease in short interest in May. As of May 28th, there was short interest totaling 1,780,000 shares, a decrease of 24.6% from the May 13th total of 2,360,000 shares. Based on an average daily volume of 1,420,000 shares, the days-to-cover ratio is presently 1.3 days. Currently, 2.8% of the shares of the stock are short sold.
View Neovasc's Short Interest.

Neovasc is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Neovasc.

Neovasc Inc. (NASDAQ:NVCN) issued its quarterly earnings results on Thursday, May, 6th. The medical equipment provider reported ($0.04) EPS for the quarter, topping the Zacks' consensus estimate of ($0.10) by $0.06. The medical equipment provider had revenue of $0.45 million for the quarter, compared to analysts' expectations of $0.60 million. Neovasc had a negative net margin of 1,425.96% and a negative trailing twelve-month return on equity of 157.95%.
View Neovasc's earnings history.

Neovasc's stock was trading at $2.21 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NVCN stock has decreased by 61.1% and is now trading at $0.8599.
View which stocks have been most impacted by COVID-19.

Neovasc shares reverse split on Friday, September 21st 2018. The 1-100 reverse split was announced on Tuesday, September 11th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 20th 2018. An investor that had 100 shares of Neovasc stock prior to the reverse split would have 1 shares after the split.

2 brokerages have issued 12 month target prices for Neovasc's stock. Their forecasts range from $2.00 to $5.00. On average, they expect Neovasc's stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 307.0% from the stock's current price.
View analysts' price targets for Neovasc or view top-rated stocks among Wall Street analysts.

Some companies that are related to Neovasc include TELA Bio (TELA), Nemaura Medical (NMRD), T2 Biosystems (TTOO), RenovaCare (RCAR), Repro Med Systems (KRMD), Titan Medical (TMDI), BrainsWay (BWAY), Repro-Med Systems (REPR), PolyPid (PYPD), Venus Concept (VERO), Liquidia (LQDA), Beyond Air (XAIR), Isoray (ISR), Pro-Dex (PDEX) and Lyra Therapeutics (LYRA).
View all of NVCN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neovasc investors own include Biopharmx (BPMX), The Allstate (ALL), Amicus Therapeutics (FOLD), Synergy Pharmaceuticals (SGYP), Rexahn Pharmaceuticals (REXN), Heat Biologics (HTBX), Protalix BioTherapeutics (PLX), Palatin Technologies (PTN), 22nd Century Group (XXII) and Amarin (AMRN).

Neovasc trades on the NASDAQ under the ticker symbol "NVCN."

Neovasc's stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.66%), GenTrust LLC (0.59%), Ameraudi Asset Management Inc. (0.59%), Royal Bank of Canada (0.14%), Citadel Advisors LLC (0.11%) and Citadel Advisors LLC (0.11%).

NVCN stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, GenTrust LLC, Ameraudi Asset Management Inc., Royal Bank of Canada, Citadel Advisors LLC, and Citadel Advisors LLC.

Shares of NVCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVCN stock can currently be purchased for approximately $0.86.

Neovasc has a market capitalization of $58.05 million and generates $1.96 million in revenue each year. The medical equipment provider earns $-28,690,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

Neovasc employs 71 workers across the globe.

The official website for Neovasc is www.neovasc.com.

Neovasc is headquartered at Suite 5138 - 13562 Maycrest Way, RICHMOND A1, V6V 2J7.

Neovasc's mailing address is Suite 5138 - 13562 Maycrest Way, RICHMOND A1, V6V 2J7. The medical equipment provider can be reached via phone at (604) 270-4344 or via email at [email protected]